{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:29:07Z","timestamp":1793744947758,"version":"4.6.1"},"reference-count":70,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CPII21\/00012"],"award-info":[{"award-number":["CPII21\/00012"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00011"],"award-info":[{"award-number":["PI20\/00011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00599"],"award-info":[{"award-number":["PI23\/00599"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PT20\/00023"],"award-info":[{"award-number":["PT20\/00023"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["LABAE235294CALO"],"award-info":[{"award-number":["LABAE235294CALO"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PROYE18046BATL2"],"award-info":[{"award-number":["PROYE18046BATL2"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["CNS2023-145267"],"award-info":[{"award-number":["CNS2023-145267"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2021 SGR 001278"],"award-info":[{"award-number":["2021 SGR 001278"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2026,2,14]]},"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, with clinical progress limited by intratumoural cellular diversity and the absence of robust, informative markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Leveraging the heterogeneity of cancer-associated fibroblasts (CAFs) within the tumour microenvironment, this study aims to identify and evaluate candidate biomarkers to support patient stratification and improve prediction of therapeutic responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We applied a multiomic approach integrating single-cell RNA sequencing, computational cell deconvolution and protein-level assessment from patient tumours, complemented by in vitro and in vivo preclinical models, to characterise stromal populations linked to CRC progression and treatment resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Retrospective analysis of over 3000 patient samples across multiple cohorts identified a distinct subset of CAFs expressing collagen triple helix repeat containing 1 (CTHRC1). CTHRC1(+) CAFs were associated with increased transforming growth factor-beta (TGF-beta) signalling and poor clinical outcomes in early and advanced disease stages. CTHRC1(+) CAFs enabled stratification of both mismatch repair-deficient\/microsatellite instability (dMMR\/MSI) and mismatch repair-proficient\/microsatellite stability (pMMR\/MSS) tumours into immune-inflamed and poorly immunogenic subtypes. Retrospective analysis of several clinical trials revealed that CTHRC1(+) CAFs are linked to resistance to immune checkpoint inhibitors in MSI and MSS tumours, suggesting therapeutic potential for combining TGF-beta blockade with immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CTHRC1-expressing CAFs represent clinically relevant biomarkers that link molecular profiling with diagnostic pathology. Our findings support the potential incorporation of CTHRC1(+) CAF assessment into routine histopathological workflows, pending prospective validation, and suggest a framework for stroma-informed CRC stratification, particularly in patients with stroma-rich, treatment-resistant tumours and pMMR\/MSS with limited therapeutic options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-336804","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:20:11Z","timestamp":1776165611000},"page":"2143-2155","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Stromal biomarker-based framework for identifying pMMR\/MSS and dMMR\/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy"],"prefix":"10.1136","volume":"75","clinical-trial-number":[{"clinical-trial-number":"nct02423343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04501094","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03436563","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03620201","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-4671","authenticated-orcid":false,"given":"Mar","family":"Iglesias Coma","sequence":"first","affiliation":[{"name":"Department of Pathology, Hospital del Mar, Barcelona, Spain"},{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Badia-Ramentol","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Martinez-Ciarpaglini","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednico Universitario, University of Valencia, Valencia, Spain"},{"name":"INCLIVA Biomedical Research Institute, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenniffer","family":"Linares","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"},{"name":"Department of Medical Oncology, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Tarazona","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"INCLIVA Biomedical Research Institute, Valencia, Spain"},{"name":"Department of Medical Oncology, Hospital Clinico Universitario, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Mulet-Margalef","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology (ICO) Badalona, Badalona, Spain"},{"name":"Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9515-8688","authenticated-orcid":false,"given":"Paula","family":"Tornero-Pi\u00f1ero","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sallent-Aragay","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-8811","authenticated-orcid":false,"given":"Alba","family":"Recort-Bascuas","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-0759","authenticated-orcid":false,"given":"Joan","family":"Gibert","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sant-Albors","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-3496","authenticated-orcid":false,"given":"Daniele V F","family":"Tauriello","sequence":"additional","affiliation":[{"name":"Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain"},{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melba","family":"Cruz-Moral","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Carreras-Gallardo","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sancho","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Morral Martinez","sequence":"additional","affiliation":[{"name":"Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garrido","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-4577","authenticated-orcid":false,"given":"Jose Luis Manzano","family":"Mozo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology (ICO) Badalona, Badalona, Spain"},{"name":"Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3691","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"INCLIVA Biomedical Research Institute, Valencia, Spain"},{"name":"Department of Medical Oncology, Hospital Clinico Universitario, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Montagut","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Department of Medical Oncology, Hospital del Mar, Barcelona, Spain"},{"name":"Pompeu Fabra University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Batlle","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain"},{"name":"Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-6131","authenticated-orcid":false,"given":"Alexandre","family":"Calon","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Hospital del Mar Research Institute (HMRIB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"2026100702350700000_75.11.2143.1","unstructured":"Amin M , Edge S , Greene F , et al . AJCC cancer staging manual. 8th edn. New York: Springer International Publishing, 2017."},{"key":"2026100702350700000_75.11.2143.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0275-y"},{"key":"2026100702350700000_75.11.2143.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"2026100702350700000_75.11.2143.4","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s43018-025-00960-z","article-title":"Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer","volume":"6","author":"Mart\u00edn-Arana","year":"2025","journal-title":"Nat Cancer"},{"key":"2026100702350700000_75.11.2143.5","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202467"},{"key":"2026100702350700000_75.11.2143.6","first-page":"314","article-title":"Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers","volume":"6","author":"Al-Shamsi","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"2026100702350700000_75.11.2143.7","first-page":"1375","article-title":"The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer","volume":"79","author":"Taieb","year":"2019","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026100702350700000_75.11.2143.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2026100702350700000_75.11.2143.9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041022","article-title":"Challenges and Therapeutic Opportunities in the dMMR\/MSI-H Colorectal Cancer Landscape","volume":"15","author":"Mulet-Margalef","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026100702350700000_75.11.2143.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.064"},{"key":"2026100702350700000_75.11.2143.11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cncr.29190","article-title":"Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer","volume":"121","author":"Moreira","year":"2015","journal-title":"Cancer"},{"key":"2026100702350700000_75.11.2143.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804588"},{"key":"2026100702350700000_75.11.2143.13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100702350700000_75.11.2143.14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","article-title":"Therapeutic targeting of mismatch repair-deficient cancers","volume":"22","author":"Johannet","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100702350700000_75.11.2143.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"2026100702350700000_75.11.2143.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"2026100702350700000_75.11.2143.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2026100702350700000_75.11.2143.18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br J Cancer"},{"key":"2026100702350700000_75.11.2143.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252"},{"key":"2026100702350700000_75.11.2143.20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3174"},{"key":"2026100702350700000_75.11.2143.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001453","article-title":"Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value","volume":"10","author":"Marisa","year":"2013","journal-title":"PLoS Med"},{"key":"2026100702350700000_75.11.2143.22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3175"},{"key":"2026100702350700000_75.11.2143.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3967"},{"key":"2026100702350700000_75.11.2143.24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy410"},{"key":"2026100702350700000_75.11.2143.25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz052"},{"key":"2026100702350700000_75.11.2143.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02258"},{"key":"2026100702350700000_75.11.2143.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz387"},{"key":"2026100702350700000_75.11.2143.28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz412"},{"key":"2026100702350700000_75.11.2143.29","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3224"},{"key":"2026100702350700000_75.11.2143.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36334-1"},{"key":"2026100702350700000_75.11.2143.31","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3225"},{"key":"2026100702350700000_75.11.2143.32","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492"},{"key":"2026100702350700000_75.11.2143.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01125-0","article-title":"What is new in cancer-associated fibroblast biomarkers?","volume":"21","author":"Zhao","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2026100702350700000_75.11.2143.34","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01013-0"},{"key":"2026100702350700000_75.11.2143.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0355-0"},{"key":"2026100702350700000_75.11.2143.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0439-x"},{"key":"2026100702350700000_75.11.2143.37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1214\/ss\/1038425655","article-title":"Flexible smoothing with B-splines and penalties","volume":"11","author":"Eilers","year":"1996","journal-title":"Statist Sci"},{"key":"2026100702350700000_75.11.2143.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2026100702350700000_75.11.2143.39","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0327-7_17"},{"key":"2026100702350700000_75.11.2143.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-018-0057-0"},{"key":"2026100702350700000_75.11.2143.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-43492-0","article-title":"Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes","volume":"9","author":"Ragulan","year":"2019","journal-title":"Sci Rep"},{"key":"2026100702350700000_75.11.2143.42","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41588-025-02380-2","article-title":"TGF-\u03b2 builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages","volume":"57","author":"Henriques","year":"2025","journal-title":"Nat Genet"},{"key":"2026100702350700000_75.11.2143.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024"},{"key":"2026100702350700000_75.11.2143.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32782-3"},{"key":"2026100702350700000_75.11.2143.45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"2026100702350700000_75.11.2143.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13061281","article-title":"Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer","volume":"13","author":"El Sissy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026100702350700000_75.11.2143.47","doi-asserted-by":"publisher","DOI":"10.23736\/s1824-4785.20.03249-5"},{"key":"2026100702350700000_75.11.2143.48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaoncol.2021.0177","article-title":"Tumor-Infiltrating Lymphocytes for Prognostic Stratification in Nonmetastatic Colon Cancer-Are We There Yet?","volume":"7","author":"Sinicrope","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026100702350700000_75.11.2143.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4"},{"key":"2026100702350700000_75.11.2143.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0863"},{"key":"2026100702350700000_75.11.2143.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"2026100702350700000_75.11.2143.52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2879"},{"key":"2026100702350700000_75.11.2143.53","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-22-3964","article-title":"Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors","volume":"29","author":"Gallois","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026100702350700000_75.11.2143.54","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.06.064"},{"key":"2026100702350700000_75.11.2143.55","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.annonc.2023.05.010","article-title":"Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability","volume":"34","author":"Ratovomanana","year":"2023","journal-title":"Ann Oncol"},{"key":"2026100702350700000_75.11.2143.56","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","article-title":"Deciphering radiological stable disease to immune checkpoint inhibitors","volume":"33","author":"Luo","year":"2022","journal-title":"Ann Oncol"},{"key":"2026100702350700000_75.11.2143.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8"},{"key":"2026100702350700000_75.11.2143.58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature New Biol"},{"key":"2026100702350700000_75.11.2143.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01355-5"},{"key":"2026100702350700000_75.11.2143.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.009"},{"key":"2026100702350700000_75.11.2143.61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"2026100702350700000_75.11.2143.62","doi-asserted-by":"crossref","first-page":"621070","DOI":"10.3389\/fcell.2020.621070","article-title":"Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy","volume":"8","author":"Linares","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026100702350700000_75.11.2143.63","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00413-6"},{"key":"2026100702350700000_75.11.2143.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.08.013"},{"key":"2026100702350700000_75.11.2143.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.12.008"},{"key":"2026100702350700000_75.11.2143.66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026100702350700000_75.11.2143.67","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00274-1"},{"key":"2026100702350700000_75.11.2143.68","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.dld.2021.06.009","article-title":"Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial","volume":"53","author":"Gallois","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2026100702350700000_75.11.2143.69","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.06.005","article-title":"LBA1 Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR\/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial","volume":"35","author":"Tougeron","year":"2024","journal-title":"Ann Oncol"},{"key":"2026100702350700000_75.11.2143.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.009"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-336804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:36:05Z","timestamp":1791365765000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-336804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,10,7]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1136\/gutjnl-2025-336804"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-336804","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}